Maintenance Notice (5:30 - 10:30 PM June 28, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding
Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 143491-57-0 | Product Number: E1007
Emtricitabine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Belgium | Japan* |
|---|---|---|---|
| 25MG |
€16.00
|
1 | 20 |
| 250MG |
€91.00
|
1 | 32 |
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | E1007 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__8H__1__0FN__3O__3S = 247.24 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container | 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 143491-57-0 |
| Reaxys Registry Number | 5908714 |
| PubChem Substance ID | 253660241 |
| Merck Index (14) | 3565 |
| MDL Number | MFCD00870151 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| Melting point | 153.0 to 157.0 °C |
| Specific rotation [a]20/D | -137.0 to -143.0 deg(C=0.25, MeOH) |
Properties (reference)
| Melting Point | 155 °C |
| Specific Rotation | -140° (C=0.25,MeOH) |
| Maximum Absorption Wavelength | 280 nm (H__2O) |
| Solubility in water | Soluble |
| Degree of solubility in water | 112 g/l 25 °C |
GHS
Related Laws:
| RTECS# | UW7360500 |
Transport Information:
| HS Number | 2934999090 |
Application
Emtricitabine (FTC): a Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Emtricitabine (FTC) is a nucleoside reverse transcriptase inhibitor (NRTI) that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). FTC, after phosphorylated by cellular enzymes to emtricitabine 5'-triphosphate (FTC-TP), inhibits HIV and HBV reverse transcriptase (HIV-RT and HBV-RT).
References
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
- Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
- Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus
- Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
- Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.